Search research articles
Contact Us
Filters
Showing results (31-40 of 300) with videos related to
Page
of 30
Sort By:
Journal of HIV Therapy
|
September 3, 2003
Antiretroviral therapy to reduce the sexual transmission of HIV
Stephen Taylor, Marta Boffito, Pietro L Vernazza
Expert Opinion on Drug Metabolism & Toxicology
|
July 26, 2006
The clinical pharmacology of antiretrovirals in development
Alan Winston, Patrick Wg Mallon, Marta Boffito
The Lancet. HIV
|
February 7, 2020
Antiretroviral resistance and management after pre-exposure to prophylaxis
Victoria Tittle, Marta Boffito, Alan McOwan, et al.
AIDS (London, England)
|
December 1, 2021
Pharmacokinetic interactions of modern antiretroviral therapy
Phumla Z Sinxadi, Saye H Khoo, Marta Boffito
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 15, 2011
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Andrew Hill, Saye Khoo, Marta Boffito, et al.
Journal of Virus Eradication
|
February 18, 2021
The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
Laura Waters, Viraj Mehta, Jaideep Gogtay, et al.
Drugs
|
December 12, 2013
New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents
Marta Boffito, Akil Jackson, Andrew Owen, et al.
Clinical Pharmacokinetics
|
October 22, 2014
Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives
Victoria Tittle, Lauren Bull, Marta Boffito, et al.
Current Opinion in HIV and AIDS
|
June 2, 2017
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing
Marta Boffito, Mohammed Lamorde, Melynda Watkins, et al.
Current Opinion in Infectious Diseases
|
January 14, 2005
The pharmacokinetics of HIV protease inhibitor combinations
Marta Boffito, Desmond Maitland, Yohan Samarasinghe, et al.
Page
of 30
Search research articles
Search
Showing results (31-40 of 300) with videos related to
Sort By:
Page
of 30
Journal of HIV Therapy
|
September 3, 2003
Antiretroviral therapy to reduce the sexual transmission of HIV
Stephen Taylor, Marta Boffito, Pietro L Vernazza
Expert Opinion on Drug Metabolism & Toxicology
|
July 26, 2006
The clinical pharmacology of antiretrovirals in development
Alan Winston, Patrick Wg Mallon, Marta Boffito
The Lancet. HIV
|
February 7, 2020
Antiretroviral resistance and management after pre-exposure to prophylaxis
Victoria Tittle, Marta Boffito, Alan McOwan, et al.
AIDS (London, England)
|
December 1, 2021
Pharmacokinetic interactions of modern antiretroviral therapy
Phumla Z Sinxadi, Saye H Khoo, Marta Boffito
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 15, 2011
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Andrew Hill, Saye Khoo, Marta Boffito, et al.
Journal of Virus Eradication
|
February 18, 2021
The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
Laura Waters, Viraj Mehta, Jaideep Gogtay, et al.
Drugs
|
December 12, 2013
New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents
Marta Boffito, Akil Jackson, Andrew Owen, et al.
Clinical Pharmacokinetics
|
October 22, 2014
Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives
Victoria Tittle, Lauren Bull, Marta Boffito, et al.
Current Opinion in HIV and AIDS
|
June 2, 2017
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing
Marta Boffito, Mohammed Lamorde, Melynda Watkins, et al.
Current Opinion in Infectious Diseases
|
January 14, 2005
The pharmacokinetics of HIV protease inhibitor combinations
Marta Boffito, Desmond Maitland, Yohan Samarasinghe, et al.
Page
of 30